Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 15;21(24):9531. doi: 10.3390/ijms21249531

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Anti-CD37 therapeutic approaches- killing mechanisms. Several therapeutics have been studied, including monoclonal antibodies (e.g., Otlertuzumab, DuoHexaBody), an antibody-drug conjugate (Naratuximab Emtansine), and chimeric antigen receptor T cells (CAR-T). Different tumor cell killing mechanisms were exploited, e.g., complement-dependent cellular cytotoxicity (CDCC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis. ITIM: immune tyrosine-based inhibitory motif; MAC: membrane attacking complex; C1q: complement component 1q; FcγR: Fc-gamma receptor; FOXO3: Forkhead box O3.